Lacosamida Zentiva

Lacosamide, the active ingredient in Lacosamida Zentiva, is a Anticonvulsant presented as a oral tablet for Oral use. It treats partial‑onset seizures and epilepsy in patients who require additional seizure control.

GNH USA supplies Lacosamida Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Lacosamide is an anticonvulsant indicated for seizure disorders and epilepsy.

Partial‑onset seizures: Reduces seizure frequency in patients with focal epilepsy. Epilepsy: Provides adjunctive therapy for seizure control in adults with refractory epilepsy. Focal epilepsy: Improves seizure management when added to existing antiepileptic regimens.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Diplopia (double vision)

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac conduction abnormalities, including PR‑interval prolongation - Hypersensitivity reactions with rash or angioedema

When prescribing Lacosamide, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: obtain baseline ECG and monitor for PR‑interval prolongation. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Concomitant antiepileptics: evaluate for additive CNS effects and adjust therapy. - Store at room temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, reducing lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may markedly decrease lacosamide exposure. - Co‑administration with other sodium‑channel blockers (e.g., phenytoin, lamotrigine): increases risk of cardiac conduction disturbances.

Moderate Interactions (Monitor Closely): - Oral contraceptives: lacosamide may lower hormonal efficacy, consider alternative contraception. - Antihypertensives: additive hypotensive effect may occur; monitor blood pressure. - Valproate or other antiepileptics: potential for altered plasma concentrations; adjust dosing as needed.